These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 26331692)

  • 1. Biomarker exposure-response relationships as the basis for rational dose selection: Lessons from a simulation exercise using a selective COX-2 inhibitor.
    Taneja A; Oosterholt SP; Danhof M; Della Pasqua O
    J Clin Pharmacol; 2016 May; 56(5):609-21. PubMed ID: 26331692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled trial of a selective COX-2 inhibitor, GW406381, in patients with postherpetic neuralgia.
    Shackelford S; Rauck R; Quessy S; Blum D; Hodge R; Philipson R
    J Pain; 2009 Jun; 10(6):654-60. PubMed ID: 19409858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-based analysis of thromboxane B₂ and prostaglandin E₂ as biomarkers in the safety evaluation of naproxen.
    Sahota T; Sanderson I; Danhof M; Della Pasqua O
    Toxicol Appl Pharmacol; 2014 Aug; 278(3):209-19. PubMed ID: 24667227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, randomized, placebo-controlled, single-dose study of the cyclooxygenase-2 inhibitor, GW406381, as a treatment for acute migraine.
    Wentz AL; Jimenez TB; Dixon RM; Aurora SK; Gold M;
    Eur J Neurol; 2008 Apr; 15(4):420-7. PubMed ID: 18312401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive population pharmacokinetic/pharmacodynamic model for a novel COX-2 inhibitor.
    Rohatagi S; Kastrissios H; Gao Y; Zhang N; Xu J; Moberly J; Wada R; Yoshihara K; Takahashi M; Truitt K; Salazar D
    J Clin Pharmacol; 2007 Mar; 47(3):358-70. PubMed ID: 17322148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
    Panara MR; Renda G; Sciulli MG; Santini G; Di Giamberardino M; Rotondo MT; Tacconelli S; Seta F; Patrono C; Patrignani P
    J Pharmacol Exp Ther; 1999 Jul; 290(1):276-80. PubMed ID: 10381787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled, dose-ranging study investigating single doses of GW406381, naproxen sodium, or placebo in patients with acute pain after third molar tooth extraction.
    Varner J; Lomax M; Blum D; Quessy S
    Clin J Pain; 2009 Sep; 25(7):577-83. PubMed ID: 19692798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury.
    Zhao FY; Spanswick D; Martindale JC; Reeve AJ; Chessell IP
    Pain; 2007 Mar; 128(1-2):78-87. PubMed ID: 17055166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an Enantioselective and Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model for Etodolac.
    de Miranda Silva C; Rocha A; Tozatto E; da Silva LM; Donadi EA; Dalla Costa T; Lanchote VL; Schmidt S; Bulitta JB
    AAPS J; 2017 Nov; 19(6):1814-1825. PubMed ID: 28875479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib.
    Giraudel JM; Toutain PL; King JN; Lees P
    J Vet Pharmacol Ther; 2009 Feb; 32(1):31-40. PubMed ID: 19161453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study.
    King JN; Rudaz C; Borer L; Jung M; Seewald W; Lees P
    Res Vet Sci; 2010 Jun; 88(3):497-506. PubMed ID: 20004922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of COX-1/COX-2 inhibition versus selective COX-2 inhibition on coronary vasodilator responses to arachidonic acid and acetylcholine.
    Gross GJ; Moore J
    Pharmacology; 2004 Jul; 71(3):135-42. PubMed ID: 15161995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.
    Beswick P; Bingham S; Bountra C; Brown T; Browning K; Campbell I; Chessell I; Clayton N; Collins S; Corfield J; Guntrip S; Haslam C; Lambeth P; Lucas F; Mathews N; Murkit G; Naylor A; Pegg N; Pickup E; Player H; Price H; Stevens A; Stratton S; Wiseman J
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5445-8. PubMed ID: 15454242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
    Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA.
    Okumura T; Sakakibara A; Murata Y; Kita Y
    Eur J Pharmacol; 2008 Jan; 578(1):97-9. PubMed ID: 17716650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
    Ehrich EW; Dallob A; De Lepeleire I; Van Hecken A; Riendeau D; Yuan W; Porras A; Wittreich J; Seibold JR; De Schepper P; Mehlisch DR; Gertz BJ
    Clin Pharmacol Ther; 1999 Mar; 65(3):336-47. PubMed ID: 10096266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of nimesulide, acetylsalicylic acid, ibuprofen and nabumetone on cyclooxygenase-1- and cyclooxygenase-2-mediated prostanoid production in healthy volunteers ex vivo.
    Kerola M; Vuolteenaho K; Kosonen O; Kankaanranta H; Sarna S; Moilanen E
    Basic Clin Pharmacol Toxicol; 2009 Jan; 104(1):17-21. PubMed ID: 19152549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing.
    Simon AM; O'Connor JP
    J Bone Joint Surg Am; 2007 Mar; 89(3):500-11. PubMed ID: 17332098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model.
    Khan AA; Brahim JS; Rowan JS; Dionne RA
    Clin Pharmacol Ther; 2002 Jul; 72(1):44-9. PubMed ID: 12152003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors.
    Huntjens DR; Danhof M; Della Pasqua OE
    Rheumatology (Oxford); 2005 Jul; 44(7):846-59. PubMed ID: 15855183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.